A randomized controlled clinical study on the effect of moxibustion on the quality of life in patients with gastric cancer
- Conditions
- gastric cancer
- Registration Number
- ITMCTR2000004191
- Lead Sponsor
- Hebei University of Chinese Meidicne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1.Patients who meet the Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Gastric Cancer (2018.V1) diagnosed as gastric cancer by cytology or histopathology;
2.According to the American Joint Committee on Cancer (AJCC) / The Union for International Cancer Control (UICC) gastric cancer TNM staging system (8th edition), patients who with gastric cancer in stage II, III and IV;
3.Patients whose inspection indicators are in line with chemotherapy indications and undergoing in chemotherapy treatment;
4.The patients age from 18 to 70 years old, regardless of gender;
5.KPS score is over 60;
6.The estimated survival time is not less than 3 months through symptoms, signs and other auxiliary examinations;
7.The patients have good compliance, understand the real situation of this study, participate voluntarily, and sign the informed consent.
1.Patients in perioperative preoperative chemotherapy
2.Pregnant or lactating women;
3..Patients with severe hepatic and renal dysfunction,or combined with severe cardiovascular and cerebrovascular diseases, diabetes, infectious diseases, etc., with obvious bleeding tendency;
4.Patients with poor compliance, or mental disorders cannot cooperate with treatment;
5.Patients have been accepted other therapeutic measures similar to this study, which may interfere with or affect the observation indicators of this trial.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the Index of Nausea, Vomiting and Retching;MD Anderson Symptom Inventory - Traditional Chinese Medicine (MDASI-TCM);European organization for research and treatment of cancer quality of life questionair (EORTC QLQ-C30+STO22);Safety Evaluation;
- Secondary Outcome Measures
Name Time Method classification criteria table for acute and subacute toxicity of anticancer drugs made by WHO;Tumor Marker: AFP, CEA, CA125, CA153/PSA, CA199;The results of routine blood test and biochemical test;